Viswanath Devanarayan

List of Publications by Year in Descending Order

35 papers	3,869 citations	23 h-index	40 g-index
40 ext. papers	4,474 ext. citations	5.9 avg, IF	4.21 L-index

#	Paper	IF	Citations
35	Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and Predict Progression from Mild Cognitive Impairment. *Journal of Alzheimer's Disease*, **2021**, 80, 311-319	4.3	0
34	Hearing Loss in Alzheimer's Disease Is Associated with Altered Serum Lipidomic Biomarker Profiles. *Cells*, **2020**, 9,	7.9	3
33	Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?. *AAPS Journal*, **2020**, 22, 127	3.7	2
32	Report on the AAPS Immunogenicity Guidance Forum. *AAPS Journal*, **2019**, 21, 55	3.7	7
31	Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. *AAPS Journal*, **2019**, 22, 7	3.7	6
30	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. *Journal of Alzheimer's Disease*, **2019**, 68, 537-550	4.3	5
29	VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD. *Alzheimer Disease and Associated Disorders*, **2019**, 33, 307-314	2.5	12
28	Patient subgroup identification for clinical drug development. *Statistics in Medicine*, **2017**, 36, 1414-1428	2.3	26
27	A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. *PLoS ONE*, **2017**, 12, e0182098	3.7	30
26	Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points. *AAPS Journal*, **2017**, 19, 1487-1498	3.7	37
25	Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge. *Alzheimer's and Dementia*, **2016**, 12, 1014-1021	1.2	54
24	Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development. *AAPS Journal*, **2016**, 18, 1-14	3.7	57
23	Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. *Bioanalysis*, **2015**, 7, 229-42	2.1	31
22	Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib. *Lung Cancer*, **2015**, 90, 296-301	5.9	10
21	A PRIM approach to predictive-signature development for patient stratification. *Statistics in Medicine*, **2015**, 34, 317-42	2.3	29
20	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity). *Bioanalysis*, **2015**, 7, 3107-24	2.1	51
19	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. *Genome Biology*, **2015**, 16, 133	18.3	212

18	Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. *Journal of Clinical Oncology*, **2015**, 33, 433-41	2.2	36
17	The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. *Nature Biotechnology*, **2014**, 32, 926-32	44.5	323
16	Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. *Alzheimer Disease and Associated Disorders*, **2013**, 27, 233-43	2.5	48
15	Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls. *Alzheimer Disease and Associated Disorders*, **2012**, 26, 322-8	2.5	27
14	Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders Extra*, **2011**, 1, 31-42	2.5	32
13	Cut Points and Performance Characteristics for Anti-Drug Antibody Assays **2011**, 287-308		7
12	Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. *Journal of Pharmaceutical and Biomedical Analysis*, **2011**, 55, 878-88	3.5	93
11	Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. *Alzheimer Disease and Associated Disorders*, **2011**, 25, 73-84	2.5	45
10	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. *Nature Biotechnology*, **2010**, 28, 827-38	44.5	644
9	Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. *Journal of Immunological Methods*, **2008**, 333, 1-9	2.5	274
8	Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. *Journal of Pharmaceutical and Biomedical Analysis*, **2008**, 48, 1267-81	3.5	434
7	Confirmatory reanalysis of incurred bioanalytical samples. *AAPS Journal*, **2007**, 9, E336-43	3.7	119
6	Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay. *Journal of Pharmaceutical and Biomedical Analysis*, **2006**, 41, 189-95	3.5	14
5	Fit-for-purpose method development and validation for successful biomarker measurement. *Pharmaceutical Research*, **2006**, 23, 312-28	4.5	572
4	Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. *Journal of Pharmaceutical and Biomedical Analysis*, **2005**, 36, 1037-44	3.5	109
3	Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. *Journal of Immunological Methods*, **2004**, 289, 1-16	2.5	509
2	Statistical Considerations in the Validation of Ligand-Binding Assays111-128		1
1	Development and Validation of Immunogenicity Assays for Preclinical and Clinical Studies193-238		1